The DOI matches its Crossref record; 23 of the 23 references it cites were found in a registry or an index.
Experience in daily practice with ipilimumab for the treatment of patients with metastatic melanoma: an early increase in lymphocyte and eosinophil counts is associated with improved survival
Open accessAbstract
Background Ipilimumab is a recently approved immunotherapy that has demonstrated an improvement in the overall survival (OS) of patients with metastatic melanoma. We report a single-institution experience in patients treated in a compassionate-use program.Patients and methods In this prospective study, patients were treated between June 2010 and September 2011. Inclusion criteria were a diagnosis of unresectable stage III or IV melanoma, at least one previous line of chemotherapy, and survival 12 weeks after the first perfusion. Four courses of ipilimumab were administered at a dose of 3 mg/kg every 3 weeks.Results Seventy-three patients were included. Median OS was 9.1 months (95% CI 6.4-11.3) from the start of ipilimumab. Immune-related adverse events were observed in 45 patients (62%), including 19 grade 3-4 events (26%). No drug-related death occurred. A lymphocyte count >1000/mm(3) at the start of the second course and an increase in the eosinophil count >100/mm(3) between the first and second infusions were correlated with an improved OS.Conclusion Ipilimumab toxic effect is manageable in real life. Biological data such as lymphocyte and eosinophil counts at the time of the second ipilimumab infusion appear to be early markers associated with better OS.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Furthermore, an elevated eosinophil count prior to treatment was associated with longer overall survival in several studies.8–12”
From Moderate-to-severe eosinophilia induced by treatment with immune checkpoint inhibitors: 37 cases from a national reference center for hypereosinophilic syndromes and the French pharmacovigilance database (2020) · cites this paper as [8]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Improved Survival with Ipilimumab in Patients with Metastatic Melanoma
Hodi, F. S., O'Day, S. J., McDermott, D. F., Weber, R. W., Sosman, J. A., Haanen, J. B., Gonzalez, R., Robert, C., Schadendorf, D., Hassel, J. C., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1003466 · Cited by 15,155
Self-citationImproved survival with vemurafenib in melanoma with BRAF V600E mutation
Chapman, P. B., Hauschild, A., Robert, C., Haanen, J. B., Ascierto, P., Larkin, J., Dummer, R., Garbe, C., Testori, A., Maio, M., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1103782 · Cited by 7,720
Self-citationFinal Version of 2009 AJCC Melanoma Staging and Classification
Balch, C. M., Gershenwald, J. E., Soong, S.-J., Thompson, J. F., Atkins, M. B., Byrd, D. R., Buzaid, A. C., Cochran, A. J., Coit, D. G., Ding, S., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2009.23.4799 · Cited by 4,653
Self-citationIpilimumab plus Dacarbazine for Previously Untreated Metastatic Melanoma
Robert, C., Thomas, L., Bondarenko, I., O'Day, S., Weber, J., Garbe, C., Lebbe, C., Baurain, J.-F., Testori, A., Grob, J.-J., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1104621 · Cited by 4,496
Self-citationEstimates of the cancer incidence and mortality in Europe in 2006
Ferlay, J., Autier, P., Boniol, M., Heanue, M., Colombet, M., & Boyle, P. (2007) · Annals of Oncology · doi:10.1093/annonc/mdl498 · Cited by 4,032
Wolchok, J. D., Hoos, A., O'Day, S. J., Weber, J. S., Hamid, O., Lebbé, C., Maio, M., Binder, M., Bohnsack, O., Nichol, G. M., et al. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-09-1624 · Cited by 3,214
Estimates of cancer incidence and mortality in Europe in 2008
Ferlay, J., Parkin, D. M., & Steliarova‐Foucher, E. (2010) · European Journal of Cancer · doi:10.1016/j.ejca.2009.12.014 · Cited by 2,323
Management of Immune-Related Adverse Events and Kinetics of Response With Ipilimumab
Weber, J. S., Kähler, K. C., & Hauschild, A. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2012.41.6750 · Cited by 1,415
Wolchok, J. D., Neyns, B., Linette, G., Negrier, S., Lutzky, J., Thomas, L., Waterfield, W., Schadendorf, D., Smylie, M., Guthrie, T., et al. (2010) · The Lancet Oncology · doi:10.1016/s1470-2045(09)70334-1 · Cited by 1,195
Management of Cutaneous Melanoma
Tsao, H., Atkins, M. B., & Sober, A. J. (2004) · New England Journal of Medicine · doi:10.1056/nejmra041245 · Cited by 869
Flagged first, then by citations
Research works printed but not linked: 1
- Squibb, 2011, YERVOY™ (ipilimumab) Immune-mediated adverse reaction management guide
Cited by
Sorted by citations
Items 101–200 of 318
Zahoor, H., Barata, P. C., Jia, X., Martin, A. M., Allman, K. D., Wood, L. S., Gilligan, T. D., Grivas, P. D., Ornstein, M. C., Garcia, J. A., et al. (2018) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-018-0425-8 · Cited by 67
Prognostic score for patients with advanced melanoma treated with ipilimumab
Diem, S., Kasenda, B., Martín-Liberal, J., Lee, A. T. J., Chauhan, D., Gore, M. E., & Larkin, J. (2015) · European Journal of Cancer · doi:10.1016/j.ejca.2015.09.007 · Cited by 66
Haanen, J. B. A. G. (2013) · European Journal of Cancer Supplements · doi:10.1016/j.ejcsup.2013.07.013 · Cited by 64
Rossi, S., Toschi, L., Castello, A., Grizzi, F., Mansi, L., & Lopci, E. (2017) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-017-3802-5 · Cited by 64
Joseph, N., McWilliam, A., Kennedy, J., Haslett, K., Mahil, J., Gavarraju, A., Mistry, H. B., van Herk, M., Finn, C. F., & Choudhury, A. (2019) · Radiotherapy and Oncology · doi:10.1016/j.radonc.2019.03.008 · Cited by 65
Omori, M., Okuma, Y., Hakozaki, T., & Hosomi, Y. (2018) · Molecular and Clinical Oncology · doi:10.3892/mco.2018.1765 · Cited by 61
Guida, M., Strippoli, S., Maule, M. M., Quaglino, P., Ramondetta, A., Chiarion‐Sileni, V., Cappellini, G. A., Queirolo, P., Ridolfi, L., Vecchio, M. D., et al. (2021) · ESMO Open · doi:10.1016/j.esmoop.2021.100064 · Cited by 60
Borcherding, N. C., Kolb, R. H., Gullicksrud, J. A., Vikas, P., Zhu, Y., & Zhang, W. (2018) · Journal of Molecular Biology · doi:10.1016/j.jmb.2018.05.030 · Cited by 60
Scanvion, Q., Béné, J., Gautier, S., Grandvuillemin, A., Le Beller, C., Chenaf, C., Etienne, N., Brousseau, S., Cortot, A. B., Mortier, L., et al. (2020) · OncoImmunology · doi:10.1080/2162402x.2020.1722022 · Cited by 59
Use of LDH and Autoimmune Side Effects to Predict Response to Ipilimumab Treatment
Dick, J., Lang, N., Slynko, A., Kopp‐Schneider, A., Schulz, C., Dimitrakopoulou‐Strauss, A., Enk, A. H., & Hassel, J. (2016) · Immunotherapy · doi:10.2217/imt-2016-0083 · Cited by 58
Cutaneous Adverse Events of Targeted Therapies for Hematolymphoid Malignancies
Ransohoff, J. D., & Kwong, B. Y. (2017) · Clinical Lymphoma Myeloma & Leukemia · doi:10.1016/j.clml.2017.07.005 · Cited by 59
Rajkumar, S., & Watson, I. R. (2016) · British Journal of Cancer · doi:10.1038/bjc.2016.195 · Cited by 61
Pérez‐Alea, M., McGrail, K., Sánchez‐Redondo, S., Fábrega, B. F., Fournet, G., Cortés, J., Muñoz‐Couselo, E., Hernández‐Losa, J., Tenbaum, S. P., Martin, G., et al. (2017) · Oncogene · doi:10.1038/onc.2017.160 · Cited by 57
Niwa, K., Kawakita, D., Nagao, T., Takahashi, H., Saotome, T., Okazaki, M., Yamazaki, K., Okamoto, I., Hirai, H., Saigusa, N., et al. (2020) · Scientific Reports · doi:10.1038/s41598-020-73965-6 · Cited by 55
Ahmad, S. S., Qian, W., Ellis, S. G., Mason, E. F., Khattak, M. A., Gupta, A., Shaw, H. M., Quinton, A., Kovarikova, J., Thillai, K., et al. (2015) · Melanoma Research · doi:10.1097/cmr.0000000000000185 · Cited by 53
Transcriptional factors targeting in cancer stem cells for tumor modulation
Chaudhary, A., Raza, S. S., & Haque, R. (2023) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2022.12.010 · Cited by 54
Koguchi, Y., Hoen, H. M., Bambina, S., Rynning, M. D., Fuerstenberg, R. K., Curti, B. D., Urba, W. J., Milburn, C. M., Bahjat, F. R., Korman, A. J., et al. (2015) · Cancer Research · doi:10.1158/0008-5472.can-15-2303 · Cited by 51
Wang, X., Zhang, B., Chen, X., Mo, H., Wu, D., Lan, B., Li, Q., Xu, B., & Huang, J. (2019) · Thoracic Cancer · doi:10.1111/1759-7714.13083 · Cited by 49
Immuno-regulatory antibodies for the treatment of cancer
Honeychurch, J., Cheadle, E. J., Dovedi, S. J., & Illidge, T. (2015) · Expert Opinion on Biological Therapy · doi:10.1517/14712598.2015.1036737 · Cited by 49
Eosinophils and Lung Cancer: From Bench to Bedside
Sibille, A., Corhay, J.-L., Louis, R. E., Ninane, V., Jérusalem, G., & Duysinx, B. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23095066 · Cited by 48
Basal neutrophil-to-lymphocyte ratio is associated with overall survival in melanoma
Lino-Silva, L. S., Salcedo‐Hernández, R. A., García-Pérez, L., Meneses-García, A., & Zepeda‐Najar, C. (2017) · Melanoma Research · doi:10.1097/cmr.0000000000000333 · Cited by 48
Innate Immune Cells and Their Contribution to T-Cell-Based Immunotherapy
Ginefra, P., Lorusso, G., & Vannini, N. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21124441 · Cited by 48
Prognostic significance of hematological profiles in melanoma patients
Gandini, S., Ferrucci, P. F., Botteri, E., Tosti, G., Barberis, M. C. P., Pala, L., Battaglia, A., Clerici, A., Spadola, G., Cocorocchio, E., et al. (2016) · International Journal of Cancer · doi:10.1002/ijc.30215 · Cited by 46
Emerging Biomarkers in Cutaneous Melanoma
Eisenstein, A. S., Gonzalez, E. C., Raghunathan, R., Xu, X., Wu, M., McLean, E. O., McGee, J. S., Ryu, B., & Alani, R. M. (2018) · Molecular Diagnosis & Therapy · doi:10.1007/s40291-018-0318-z · Cited by 48
Roles for receptor tyrosine kinases in tumor progression and implications for cancer treatment
Ghosh, S., Marrocco, I., & Yarden, Y. (2020) · Advances in cancer research · doi:10.1016/bs.acr.2020.04.002 · Cited by 48
Prognostic biomarkers for immunotherapy with ipilimumab in metastatic melanoma
Nyakas, M., Aamdal, E., Jacobsen, K. D., Guren, T. K., Aamdal, S., Thorin‐Hagene, K., Brunsvig, P. F., Yndestad, A., Halvorsen, B. L., Taskén, K. A., et al. (2019) · Clinical & Experimental Immunology · doi:10.1111/cei.13283 · Cited by 46
Mechanism and potential predictive biomarkers of immune checkpoint inhibitors in NSCLC
Qu, J., Jiang, M., Wang, L., Zhao, D., Qin, K., Wang, Y., Tao, J., & Zhang, X. (2020) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2020.109996 · Cited by 46
Chasset, F., Pagès, C., Biard, L., Roux, J., Sidina, I., Madelaine, I., Basset‐Séguin, N., Viguier, M. A., Madjlessi-Ezra, N., Schneider, P., et al. (2015) · European Journal of Dermatology · doi:10.1684/ejd.2014.2471 · Cited by 45
Diem, S., Ali, O. H., Ackermann, C. J., Bomze, D., Koelzer, V. H., Jochum, W., Speiser, D. E., Mertz, K. D., & Flatz, L. (2017) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-017-2061-4 · Cited by 45
Deregulated transcription factors in the emerging cancer hallmarks
Hasan, A., Khan, N. A., Shahab Uddin, M. S., Khan, A. Q., & Steinhoff, M. S. (2023) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2023.12.001 · Cited by 45
Basler, L., Andratschke, N. H., Ehrbar, S., Gückenberger, M., & Tanadini‐Lang, S. (2018) · Radiation Oncology · doi:10.1186/s13014-018-0952-y · Cited by 44
Zhuo, M., Chen, H., Zhang, T., Yang, X., Zhong, J., Wang, Y., An, T., Wu, M., Wang, Z., Huang, J., et al. (2018) · Cancer Biomarkers · doi:10.3233/cbm-171089 · Cited by 42
Immunostimulatory Effects of Radiotherapy for Local and Systemic Control of Melanoma: A Review
Takahashi, J., & Nagasawa, S. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21239324 · Cited by 44
Lerner, S. P., Bajorin, D. F., Dinney, C. P., Efstathiou, J. A., Groshen, S. G., Hahn, N. M., Hansel, D. E., Kwiatkowski, D. J., O’Donnell, M. A., Rosenberg, J. E., et al. (2016) · Bladder Cancer · doi:10.3233/blc-160053 · Cited by 42
Ferrucci, P. F., Gandini, S., Cocorocchio, E., Pala, L., Baldini, F., Mosconi, M., Cappellini, G. C. A., Albertazzi, E., & Martinoli, C. (2017) · Oncotarget · doi:10.18632/oncotarget.19748 · Cited by 41
Steele, M. L., Axtner, J., Happe, A., Kröz, M., Matthes, H., & Schad, F. (2014) · Integrative Cancer Therapies · doi:10.1177/1534735414563977 · Cited by 44
Hyperprogression: A novel response pattern under immunotherapy
Han, X., Alu, A., Xiao, Y., Wei, Y., & Wei, X. (2020) · Clinical and Translational Medicine · doi:10.1002/ctm2.167 · Cited by 41
Relecom, A., Merhi, M., Inchakalody, V. P., Shahab Uddin, M. S., Rinchai, D., Bedognetti, D., & Dermime, S. (2021) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-021-01872-3 · Cited by 41
Roger, A., Groh, M., Lorillon, G., Le Pendu, C., Maillet, J., Arangalage, D., Tazi, A., Lebbe, C., Baroudjian, B., & Delyon, J. (2019) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2018-213857 · Cited by 39
Self-citationSun, R., Champiat, S., Dercle, L., Aspeslagh, S., Álvarez, E. C., Limkin, E. J., Baldini, C., Postel-Vinay, S. C., Hollebecque, A., Massard, C., et al. (2017) · European Journal of Cancer · doi:10.1016/j.ejca.2017.07.033 · Cited by 39
GM-CSF and ipilimumab therapy in metastatic melanoma: Clinical outcomes and immunologic responses
Kwek, S. S., Kahn, J. G., Greaney, S. K., Lewis, J., Cha, E., Zhang, L., Weber, R. W., Leonard, L., Markovic, S. N., Fong, L. H., et al. (2015) · OncoImmunology · doi:10.1080/2162402x.2015.1101204 · Cited by 35
Ouwerkerk, W., van den Berg, M., van der Niet, S., Limpens, J., & Luiten, R. M. (2019) · Melanoma Research · doi:10.1097/cmr.0000000000000589 · Cited by 38
Nishikawa, D., Suzuki, H., Beppu, S., Terada, H., Sawabe, M., Kadowaki, S., Sone, M., & Hanai, N. (2020) · Cancer Science · doi:10.1111/cas.14706 · Cited by 38
Castro, M. P., & Goldstein, N. S. (2015) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-015-0104-y · Cited by 36
Bcl6 Preserves the Suppressive Function of Regulatory T Cells During Tumorigenesis
Li, Y., Wang, Z., Lin, H., Wang, L., Chen, X., Liu, Q., Zuo, Q., Hu, J., Wang, H., Guo, J., et al. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.00806 · Cited by 32
Jung, M., Lee, J., Kim, T. M., Lee, D. H., Kang, J., Oh, S. Y., Lee, S. J., & Shin, S. J. (2016) · Cancer Research and Treatment · doi:10.4143/crt.2016.024 · Cited by 35
Ghebeh, H., Elshenawy, M. A., Alsayed, A., & Al‐Tweigeri, T. (2022) · Immunotherapy · doi:10.2217/imt-2021-0149 · Cited by 37
Ma, Y., Ma, X., Wang, J., Wu, S., Wang, J., & Cao, B. (2022) · World Journal of Surgical Oncology · doi:10.1186/s12957-022-02695-y · Cited by 34
Gandhi, S., Pandey, M. R., Ammannagari, N., Wang, C., Bucsek, M. J., Hamad, L., Repasky, E. A., & Ernstoff, M. S. (2020) · Immunotherapy · doi:10.2217/imt-2019-0064 · Cited by 33
Chu, C., Chiu, T.-H., Wang, C., Chang, W., Huang, A. C., Liu, C., Wang, C., Ko, H., Chung, F., Hsu, P., et al. (2020) · Thoracic Cancer · doi:10.1111/1759-7714.13426 · Cited by 34
Kijima, T., Yamamoto, H., Saito, K., Kusuhara, S., Yoshida, S., Yokoyama, M., Matsuoka, Y., Numao, N., Sakai, Y., Matsubara, N., et al. (2020) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-020-02709-2 · Cited by 34
Find the Flame: Predictive Biomarkers for Immunotherapy in Melanoma
Garutti, M., Bonin, S., Buriolla, S., Bertoli, E., Pizzichetta, M. A., Zalaudek, I., & Puglisi, F. (2021) · Cancers · doi:10.3390/cancers13081819 · Cited by 38
Biomarkers related to immune checkpoint inhibitors therapy
Li, N., Hou, X., Huang, S., Tai, R., Lei, L., Li, S., Abuliz, A., Wang, G., & Yang, S. (2022) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2021.112470 · Cited by 34
Harnessing myeloid cells in cancer
Park, S., Pylaeva, E., Bhuria, V., Gambardella, A. R., Schiavoni, G., Mougiakakos, D., Kim, S.-H., & Jabłońska, J. (2025) · Molecular Cancer · doi:10.1186/s12943-025-02249-2 · Cited by 35
Ipilimumab reshapes T cell memory subsets in melanoma patients with clinical response
Felix, J., Lambert, J., Roelens, M., Maubec, E., Guermouche, H., Pages, C., Sidina, I., Cordeiro, D. J., Maki, G., Chasset, F., et al. (2016) · OncoImmunology · doi:10.1080/2162402x.2015.1136045 · Cited by 32
Diem, S., Fässler, M., Bomze, D., Ali, O. H., Berner, F., Niederer, R., Hillmann, D., Mangana, J., Levesque, M. P., Dummer, R., et al. (2019) · Journal of Immunotherapy · doi:10.1097/cji.0000000000000255 · Cited by 32
Immune checkpoint inhibitor-induced diarrhea and colitis: an overview
Zoghbi, M., Burk, K. J., Haroun, E., Saadé, M., & Carreras, M. T. C. (2024) · Supportive Care in Cancer · doi:10.1007/s00520-024-08889-2 · Cited by 31
What have we learned from cancer immunotherapy in the last 3 years?
Ascierto, P. A., & Marincola, F. M. (2014) · Journal of Translational Medicine · doi:10.1186/1479-5876-12-141 · Cited by 29
Jacquelot, N., Pitt, J. M., Enot, D. P., Roberti, M. P., Duong, C. P. M., Rusakiewicz, S., Eggermont, A. M. M., & Zitvogel, L. (2017) · OncoImmunology · doi:10.1080/2162402x.2017.1299303 · Cited by 29
Self-citationBiomarkers Associated with Clinical Outcome of Advanced Melanoma Patients Treated with Ipilimumab
Balatoni, T., Ladányi, A., Fröhlich, G., Czirbesz, K., Kovacs, P. L., Pánczél, G., Bence, E., Plótár, V., & Liszkay, G. (2018) · Pathology & Oncology Research · doi:10.1007/s12253-018-0466-9 · Cited by 30
Monitoring checkpoint inhibitors: predictive biomarkers in immunotherapy
Zhang, M., Yang, H. J., Hua, W., Zhong, L., Xu, Z., & Qian, Q. (2019) · Frontiers of Medicine · doi:10.1007/s11684-018-0678-0 · Cited by 33
Postow, M. A., Chasalow, S. D., Kuk, D., Panageas, K. S., Cheng, M. L., Yuan, J. D., & Wolchok, J. D. (2019) · Melanoma Research · doi:10.1097/cmr.0000000000000633 · Cited by 31
Onesti, C. E., Josse, C., Boulet, D., Thiry, J., Beaumecker, B., Bours, V., & Jérusalem, G. (2020) · OncoImmunology · doi:10.1080/2162402x.2020.1761176 · Cited by 31
Pu, D., Xu, Q., Zhou, L., Zhou, Y., Liu, J., & Ma, X. (2021) · Thoracic Cancer · doi:10.1111/1759-7714.14152 · Cited by 29
The Ipilimumab Lesson in Melanoma: Achieving Long-Term Survival
Delyon, J., Maio, M., & Lebbé, C. (2015) · Seminars in Oncology · doi:10.1053/j.seminoncol.2015.02.005 · Cited by 31
Self-citationEosinophil-cationic protein - a novel liquid prognostic biomarker in melanoma
Krückel, A., Moreira, A., Fröhlich, W., Schuler, G., & Heinzerling, L. (2019) · BMC Cancer · doi:10.1186/s12885-019-5384-z · Cited by 31
Immune Profiling of Cancer Patients Treated with Immunotherapy: Advances and Challenges
Pilla, L., & Maccalli, C. (2018) · Biomedicines · doi:10.3390/biomedicines6030076 · Cited by 29
Whitman, E. D., Liu, F. X., Cao, X., Diede, S. J., Haiderali, A., & Abernethy, A. P. (2018) · Future Oncology · doi:10.2217/fon-2018-0620 · Cited by 29
Eosinophilia in cancer and its regulation by sex hormones
Artham, S., Chang, C., & McDonnell, D. P. (2022) · Trends in Endocrinology and Metabolism · doi:10.1016/j.tem.2022.11.002 · Cited by 29
Strategies for Predicting Response to Checkpoint Inhibitors
Zappasodi, R., Wolchok, J. D., & Merghoub, T. (2018) · Current Hematologic Malignancy Reports · doi:10.1007/s11899-018-0471-9 · Cited by 29
Systematic evaluation of immune regulation and modulation
Stroncek, D. F., Butterfield, L. H., Cannarile, M. A., Dhodapkar, M. V., Greten, T. F., Grivel, J., Kaufman, D. R., Kong, H. H., Korangy, F., Lee, P. P., et al. (2017) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-017-0223-8 · Cited by 30
Candidate immune biomarkers for radioimmunotherapy
Lévy, A., Nigro, G., Sansonetti, P. J., & Deutsch, É. (2017) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2017.02.006 · Cited by 28
Dual checkpoint inhibitor-associated eosinophilic enteritis
Yang, J., Lagana, S. M., Saenger, Y. M., & Carvajal, R. D. (2019) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-019-0743-5 · Cited by 27
Zhang, Y., Liu, B., Kotenko, S. V., & Li, W. (2022) · Medicine · doi:10.1097/md.0000000000029536 · Cited by 31
Effects of a novel Nodal-targeting monoclonal antibody in melanoma
Strizzi, L., Sandomenico, A., Margaryan, N. V., Focà, A., Sanguigno, L., Bodenstine, T. M., Chandler, G. S., Reed, D. W., Gilgur, A., Seftor, E. A., et al. (2015) · Oncotarget · doi:10.18632/oncotarget.6049 · Cited by 26
Li, S., Zou, J., Liu, C. X., Jiao, X., Gong, J., Li, J., Wang, Z., Lu, M. S., Lü, Z., & Shen, L. (2020) · Clinical Immunology · doi:10.1016/j.clim.2020.108345 · Cited by 25
Link, B., Crigna, A. T., Hölzel, M., Giordano, F. A., & Golubnitschaja, O. (2021) · Journal of Clinical Medicine · doi:10.3390/jcm10215124 · Cited by 27
Onesti, C. E., Josse, C., Poncin, A., Frères, P., Poulet, C., Bours, V., & Jérusalem, G. (2018) · Oncotarget · doi:10.18632/oncotarget.26120 · Cited by 26
Caliman, E., Fancelli, S., Ottanelli, C., Mazzoni, F., Paglialunga, L., Lavacchi, D., Michelet, M. R. G., Giommoni, E., Napolitano, B., Scolari, F., et al. (2022) · Cancer Treatment and Research Communications · doi:10.1016/j.ctarc.2022.100603 · Cited by 24
Gündüz, Ş., Göksu, S. S., Arslan, D., Tatlı, A. M., Uysal, M., Gündüz, U. R., Sevinc, M. M., Çoşkun, H. Ş., Bozcuk, H. S., Mutlu, H., et al. (2015) · Molecular and Clinical Oncology · doi:10.3892/mco.2015.610 · Cited by 25
Lang, B. M., Peveling‐Oberhag, A., Faidt, D., Hötker, A. M., Weyer‐Elberich, V., Grabbe, S., & Loquai, C. (2018) · Medical Oncology · doi:10.1007/s12032-018-1084-9 · Cited by 25
Verhaart, S. L., Abu‐Ghanem, Y., Mulder, S. F., Oosting, S. F., Veldt, A. A. M. V. D., Osanto, S., Aarts, M. J. B., Houtsma, D., Peters, F. P. J., Groenewegen, G., et al. (2020) · Clinical Genitourinary Cancer · doi:10.1016/j.clgc.2020.10.003 · Cited by 25
Immunity and Breast Cancer: Focus on Eosinophils
Poncin, A., Onesti, C. E., Josse, C., Boulet, D., Thiry, J., Bours, V., & Jérusalem, G. (2021) · Biomedicines · doi:10.3390/biomedicines9091087 · Cited by 25
Herrmann, T., Ginzac, A., Molnar, I., Bailly, S., Durando, X., & Mahammedi, H. (2021) · Cancer Medicine · doi:10.1002/cam4.4208 · Cited by 25
What does the future hold for immunotherapy in cancer?
Naidoo, J., Li, B. T., Schindler, K., & Page, D. B. (2016) · Annals of Translational Medicine · doi:10.21037/atm.2016.04.05 · Cited by 22
Clinical Activity, Toxicity, Biomarkers, and Future Development of CTLA-4 Checkpoint Antagonists
Callahan, M. K., & Wolchok, J. D. (2015) · Seminars in Oncology · doi:10.1053/j.seminoncol.2015.05.008 · Cited by 23
Furubayashi, N., Minato, A., Negishi, T., Sakamoto, N., Song, Y., Hori, Y., Tomoda, T., Tamura, S., Kuroiwa, K., Seki, N., et al. (2021) · Cancer Management and Research · doi:10.2147/cmar.s333823 · Cited by 24
Lou, Y., Marin-Acevedo, J. A., Vishnu, P., Manochakian, R., Dholaria, B., Soyano, A. E., Luo, Y., Zhang, Y., & Knutson, K. L. (2019) · Immunotherapy · doi:10.2217/imt-2018-0128 · Cited by 23
Gambichler, T., Brown, V., Steuke, A. ‐., Schmitz, L., Stockfleth, E., & Susok, L. (2017) · Journal of the European Academy of Dermatology and Venereology · doi:10.1111/jdv.14629 · Cited by 22
Immunologic Correlates in the Course of Treatment With Immunomodulating Antibodies
Weide, B., Di Giacomo, A. M., Fonsatti, E., & Zitvogel, L. (2015) · Seminars in Oncology · doi:10.1053/j.seminoncol.2015.02.016 · Cited by 21
Self-citationCurrent knowledge of Ipilimumab and its use in treating non-small cell lung cancer
Pinto, J. A., Raez, L. E., Oliveres, H., & Rolfo, C. D. (2019) · Expert Opinion on Biological Therapy · doi:10.1080/14712598.2019.1610380 · Cited by 22
Wahl, R. U., Leijs, M. M., Araujo, A., & Rübben, A. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21062020 · Cited by 20
Towards Immunotherapy-Induced Normalization of the Tumor Microenvironment
Melo, V. A., Bremer, E., & Martin, J. D. (2022) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2022.908389 · Cited by 20
Ammann, N. L., Schwietzer, Y. F., Meß, C., Stadler, J.-C., Geidel, G., Kött, J., Pantel, K., Schneider, S. W., Utikal, J. S., Bauer, A. T., et al. (2022) · Cancers · doi:10.3390/cancers14225676 · Cited by 23
Richtig, G., Kienzl, M., Rittchen, S., Roula, D., Eberle, J., Sarif, Z., Pichler, M., Höefler, G., & Heinemann, Á. (2023) · Biology · doi:10.3390/biology12050706 · Cited by 20
Wang, Y., Zhang, H., Yang, Y., Zhang, T., & Ma, X. (2019) · Frontiers in Oncology · doi:10.3389/fonc.2019.00995 · Cited by 20
Bai, R., Li, L., Chen, X., Chen, N., Song, W., Zhang, Y., Lv, Z., Han, F., Zhao, Y., Li, W., et al. (2021) · Journal of Oncology · doi:10.1155/2021/9935076 · Cited by 19
Russo, G. L., Prelaj, A., Dolezal, J. M., Beninato, T., Agnelli, L., Triulzi, T., Fabbri, A., Lorenzini, D., Ferrara, R., Brambilla, M., et al. (2023) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2023-006833 · Cited by 20
Overcoming Resistance to Immunotherapy in Advanced Cutaneous Squamous Cell Carcinoma
García‐Sancha, N., Corchado‐Cobos, R., Bellido-Hernández, L., Román‐Curto, C., Álvarez, E. C., Pérez‐Losada, J., Órfão, A., & Cañueto, J. (2021) · Cancers · doi:10.3390/cancers13205134 · Cited by 21
Overcoming Immune Resistance With Radiation Therapy in Prostate Cancer
Mulvey, A., Muggeo-Bertin, E., Berthold, D., & Herrera, F. G. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.859785 · Cited by 18
Metadata
- Authors
- Delyon, J., Mateus, C., Lefeuvre, D., Lanoy, E., Zitvogel, L., Chaput, N., Roy, S., Eggermont, A. M. M., Routier, E., & Robert, C.
- Affiliations
- Institut Gustave Roussy (FR)
- Université Paris-Sud (FR)
- Inserm (FR)
- Corresponding author
- Delyon, J.
- Venue
- Annals of Oncology
- Publisher
- Elsevier BV
- Published
- 2013-06
- Volume
- 24
- Issue
- 6
- Pages
- 1697-1703
- ISSN
- 0923-7534 (ISSN-L)
- OpenAlex
- W2107863654
- Semantic Scholar
- 227acc6dc2205788c75d438e03d62ffe4cfd3073
- Cited by
- 318
- References
- 23
- Citations by year
- 2026: 6 · 2025: 9 · 2024: 10 · 2023: 11 · 2022: 21 · 2021: 28 · 2020: 36 · 2019: 31 · 2018: 31 · 2017: 43 · 2016: 36 · 2015: 32 · 2014: 13 · 2013: 9
- FWCI
- 16.06
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Licence
- Locations
- Annals of Oncology (publishedVersion)
- PubMed (publishedVersion)
- HighWire Press Open Archive (submittedVersion)
- Topics
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Health Sciences › Medicine › Oncology › Cutaneous Melanoma Detection and Management
- Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
- Keywords
- ipilimumab, metastatic melanoma, immune checkpoint inhibitors, overall survival, lymphocyte count, eosinophil count, immune-related adverse events, prognostic factors, compassionate use program
- MeSH terms
- Ipilimumab, Adult, Aged, Aged, 80 and over, Antibodies, Monoclonal, Eosinophils, Female, Humans, Lymphocytes, Male, Melanoma, Middle Aged, Prospective Studies, Skin Neoplasms, Time Factors, Survival Rate, Treatment Outcome, Lymphocyte Count, Young Adult
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
